Analysis of sunitinib malate, a multi-targeted tyrosine kinase inhibitor: A critical review

被引:6
|
作者
AboulMagd, Asmaa M. [1 ]
Abdelwahab, Nada S. [1 ,2 ]
机构
[1] Nahda Univ NUB, Dept Pharmaceut Chem, Fac Pharm, Bani Suwayf, Egypt
[2] Beni Suef Univ, Dept Pharmaceut Analyt Chem, Fac Pharm, Bani Suwayf, Egypt
关键词
Analytical methods; Sunitinib malate; Multi-targeted tyrosine kinase inhibitor; Therapeutic drug monitoring; N-DESETHYL SUNITINIB; MICELLAR LIQUID-CHROMATOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; LC-MS/MS METHOD; HUMAN PLASMA; ACTIVE METABOLITE; SIMULTANEOUS QUANTIFICATION; CAPILLARY-ELECTROPHORESIS; MULTIKINASE INHIBITOR; VALIDATION;
D O I
10.1016/j.microc.2021.105926
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor. This work presents a review of characteristics and analytical methods applied for its determination due to the impact of developing effective and reliable analytical methods for quality control analysis, therapeutic drug monitoring, pharmacokinetics, and bioavailability studies. Most of the published methods depended on LC/MS/MS; also ultraviolet spectrophotometric, chemiluminescence, electrochemical, capillary electrophoresis, high-performance thin-layer chromatography, and high-performance liquid chromatography methods were used for estimation of sunitinib. A discussion presented here highlighted the need for developing alternative methods that are money and time saving, need minimum sample pre-treatment steps, consume less toxic solvents, and hence have minimum residue. Also, the literature revealed a deficiency in studying possible drug-drug pharmacokinetic interactions.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma
    Sun Fu-kang
    He Hong-chao
    Su Ting-wei
    Zhou Wen-long
    Huang Xin
    Dai Jun
    Shen Zhou-jun
    [J]. CHINESE MEDICAL JOURNAL, 2012, 125 (12) : 2231 - 2234
  • [2] Phase II evaluation of sunitinib malate, a multi-targeted inhibitor of receptor tyrosine kinases, in patients with myelofibrosis
    Tam, Constantine S.
    Thomas, Deborah A.
    Ravandi, Farhad
    Richardson, Catherine D.
    Borthakur, Gautarn
    Burger, Jan A.
    Estey, Elilua
    Kantarjian, Hagop
    Verstovsek, Srdan
    [J]. BLOOD, 2007, 110 (11) : 1039A - 1039A
  • [3] Food does not effect the pharmacolkinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor, in healthy subjects.
    Bello, C
    Laurie, S
    Zhou, JH
    Verkh, L
    Smeraglia, J
    Mount, J
    Klamerus, K
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9076S - 9076S
  • [4] Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
    Huang, Qiang
    Zhou, Changhua
    Chen, Xiao
    Dong, Bing
    Chen, Siqi
    Zhang, Ning
    Liu, Yawei
    Li, Anrong
    Yao, Meicun
    Miao, Ji
    Li, Qing
    Wang, Zhong
    [J]. PLOS ONE, 2015, 10 (10):
  • [5] Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib
    Chung, Caroline
    Dawson, Laura A.
    Joshua, Anthony M.
    Brade, Anthony M.
    [J]. ANTI-CANCER DRUGS, 2010, 21 (02) : 206 - 209
  • [6] Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
    Bello, Carlo L.
    Sherman, Laurie
    Zhou, Jihao
    Verkh, Lev
    Smeraglia, John
    Mount, Janessa
    Klamerus, Karen J.
    [J]. ANTI-CANCER DRUGS, 2006, 17 (03) : 353 - 358
  • [7] Sunitinib malate -: Oncolytic drug multitargeted tyrosine kinase inhibitor
    McIntyre, JA
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2005, 30 (08) : 785 - 792
  • [8] A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma
    Li, Jia
    Zou, Chang-Lin
    Zhang, Zhi-Ming
    Lv, Lian-Jie
    Qiao, Hai-Bo
    Chen, Xiu-Ju
    [J]. MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 7105 - 7111
  • [9] Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib
    Noppadon Kongsuphon
    Maturos Soukavanitch
    Noramon Teeraaumpornpunt
    Jitprapa Konmun
    Touch Ativitavas
    Nuttapong Ngamphaiboon
    [J]. Journal of Gastrointestinal Cancer, 2019, 50 : 601 - 603
  • [10] Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib
    Kongsuphon, Noppadon
    Soukavanitch, Maturos
    Teeraaumpornpunt, Noramon
    Konmun, Jitprapa
    Ativitavas, Touch
    Ngamphaiboon, Nuttapong
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (03) : 601 - 603